| Bevacizumab (avastin) for the treatment of retinopathy of prematurity. | |
| | |
MedLine Citation:
|
PMID: 22763251 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Retinopathy of prematurity (ROP) is a vasoproliferative disorder of the eye that threatens to impair vision in premature infants.1 It is estimated that at least 50 percent of infants with a birth weight of <1,250 g develop ROP, with 10 percent progressing to Stage 3.2 Treatment modalities for ROP have evolved over the past two decades. Historically, treatment for ROP has ranged from cryotherapy in the 1980s to laser photocoagulation in the 1990s. Recent advances have expanded the options available for the treatment of ROP to include antivascular endothelial growth factor (anti-VEGF) therapy currently under investigation.3 This column describes the mechanism of action and review of the angiogenesis inhibitor, bevacizumab (Avastin), as a potential option for the treatment of ROP. |
| | |
Authors:
|
Michele J Beaulieu |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Neonatal network : NN Volume: 31 ISSN: 1539-2880 ISO Abbreviation: Neonatal Netw Publication Date: 2012 Jul |
Date Detail:
|
Created Date: 2012-07-05 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8503921 Medline TA: Neonatal Netw Country: United States |
Other Details:
|
Languages: eng Pagination: 242-7 Citation Subset: N |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Neonatal mythbusters: evaluating the evidence for and against pharmacologic and nonpharmacologic man...
Next Document: Information literacy: using computers to connect practice to evidence.